TherapeuticsMD appoints Hugh O'Dowd as CEO; founder Finizio becomes Vice Chair

TherapeuticsMD, Inc.

Hugh O'Dowd, formerly President, appointed CEO on Dec 14, 2021 and director on Dec 18.
Robert G. Finizio steps down as CEO but remains Vice Chair of the Board.
Finizio's separation is termination without 'Cause'; he receives contractual separation benefits.
O'Dowd's existing employment agreement (filed Aug 9, 2021) continues unchanged.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Hugh O'Dowd

Chief Executive Officer

TXMD · TherapeuticsMD, Inc.

Effective: 2021-12-14
Filed: December 20, 2021, 6:59 PM ET

On December 14, 2021, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Mr. Hugh O’Dowd, the Company’s President, as the Company’s Chief Executive Officer

Role change

Robert G. Finizio

Chief Executive Officer

TXMD · TherapeuticsMD, Inc.

Effective: 2021-12-14
Successor: Hugh O'Dowd
Filed: December 20, 2021, 6:59 PM ET

Mr. Finizio’s separation as the Company’s Chief Executive Officer is a termination without “Cause,” as defined in that certain employment agreement

Appointed

Hugh O'Dowd

director

TXMD · TherapeuticsMD, Inc.

Effective: 2021-12-18
Filed: December 20, 2021, 6:59 PM ET

on December 18, 2021, the Board appointed Mr. O'Dowd as a director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Hugh O'Dowd was appointed as Chief Executive Officer at TherapeuticsMD, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On December 14, 2021, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Mr. Hugh O’Dowd, the Company’s President, as the Company’s Chief Executive Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Robert G. Finizio was terminated as Chief Executive Officer at TherapeuticsMD, Inc..

Action: terminated
Role: Chief Executive Officer

Exact text from the filing

Mr. Finizio’s separation as the Company’s Chief Executive Officer is a termination without “Cause,” as defined in that certain employment agreement

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Hugh O'Dowd was appointed as director at TherapeuticsMD, Inc..

Action: appointed
Role: director

Exact text from the filing

on December 18, 2021, the Board appointed Mr. O'Dowd as a director.

View on SEC.gov

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-060676

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.